BioSpace News Archive

Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced that the underwriters of its previously announced initial public offering of 12,000,000 shares of common stock have exercised their option to purchase additional shares of common stock at the public offering price of $18.00

NGM Biopharmaceuticals, Inc. announced that, effective March 13, 2020, Aetna Wun Trombley, Ph.D. will step down as President and Chief Operating Officer of the company to assume the role of Chief Executive Officer at an undisclosed privately held company.

Letter of Intent Provides for Continued Local Governance, Ongoing Community Commitment

The first mobile CT scan cabin produced by Yangzhou Tailee Special Equipment Co Ltd has been put into use in a hospital in Huanggang, one of the worst hit cities by the coronavirus outbreak in Hubei province, to help with the battle against the epidemic.

Blue Cross and Blue Shield of Kansas City announces it is taking specific steps to ensure our members’ access to testing, medications and virtual care, as it monitors the spread of the new coronavirus, or COVID-19.

CHARLOTTE, N.C., March 09, 2020 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (Nasdaq: XRAY), the Dental Solutions Company, today announced that it will participate in the 2020 Barclays Global Healthcare Conference on March 11 th . Don Casey, Chief Executive Officer, will represent the company and is scheduled to participate in a fireside chat at 11:45AM Eastern Time. Investors and other interested parties will be able to access a live audio webcast of the presentation by vi

Capital BlueCross announced steps to give its members easier, more affordable access to the care that can keep them healthy and help slow the spread of COVID-19.

NKMax America announced that Dr. Paul Song, Vice Chairman and Chief Medical Officer of NKMax America, will present at Cambridge Healthtech Institutes 5th Annual Combination Immunotherapy: Targeting Immunotherapy Combinations for Increased Clinical Efficacy conference taking place March 11 -12, 2020.

Xenon’s Robust Neurology Pipeline of Proprietary and Partnered Programs Advances with Multiple Important Milestone Opportunities Anticipated in 2020 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, March 09, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2019 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Offi

PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) today announced the appointment of Edward A. Imbrogno as the Company’s Vice President and Chief Financial Officer. Mr. Imbrogno jo